The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges
Open accessAbstract
Cancer is one of the main causes of death worldwide. To date, and despite the advances in conventional treatment options, therapy in cancer is still far from optimal due to the non-specific systemic biodistribution of antitumor agents. The inadequate drug concentrations at the tumor site led to an increased incidence of multiple drug resistance and the appearance of many severe undesirable side effects. Nanotechnology, through the development of nanoscale-based pharmaceuticals, has emerged to provide new and innovative drugs to overcome these limitations. In this review, we provide an overview of the approved nanomedicine for cancer treatment and the rationale behind their designs and applications. We also highlight the new approaches that are currently under investigation and the perspectives and challenges for nanopharmaceuticals, focusing on the tumor microenvironment and tumor disseminate cells as the most attractive and effective strategies for cancer treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“Thus, the clinical benefits of nanomedicines should be clear to justify higher prices compared to conventional therapeutics [147].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846 · cited 2×
“This heterogeneity is the main cause that limits the therapeutic value of many drugs [4], and it is further associated with a fatal disease [10,11].”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2499 · Cited by 3,429
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Microenvironmental regulation of tumour angiogenesis
De Palma, M., Biziato, D., & Petrova, T. V. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.51 · Cited by 1,847
Immunological properties of engineered nanomaterials
Dobrovolskaia, M. A., & McNeil, S. E. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.223 · Cited by 1,823
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Applying the principles of stem-cell biology to cancer
Pardal, R., Clarke, M. F., & Morrison, S. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1232 · Cited by 1,624
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Barua, S., & Mitragotri, S. (2014) · Nano Today · doi:10.1016/j.nantod.2014.04.008 · Cited by 1,257
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Targeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Challenges in Development of Nanoparticle-Based Therapeutics
Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173
Cancer stem cells: an evolving concept
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3184 · Cited by 1,171
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment
Phi, L. T. H., Sari, I. N., Yang, Y.-G., Lee, S.-H., Jun, N., Kim, K. S., Lee, Y. K., & Kwon, H. Y. (2018) · Stem Cells International · doi:10.1155/2018/5416923 · Cited by 994
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Cancer stem cells as key drivers of tumour progression
Ayob, A. Z., & Ramasamy, T. S. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0426-4 · Cited by 910
Cancer Stem Cells: Basic Concepts and Therapeutic Implications
Nassar, D., & Blanpain, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044438 · Cited by 869
Progress in Nanomedicine: Approved and Investigational Nanodrugs.
Ventola, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 835
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Effects of nanomaterial physicochemical properties on in vivo toxicity
Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.010 · Cited by 811
Cancer active targeting by nanoparticles: a comprehensive review of literature
Bazak, R., Houri, M., El Achy, S., Kamel, S., & Refaat, T. (2015) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1767-3 · Cited by 756
Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Challita-Eid, P. M., Satpayev, D., Yang, P., An, Z., Morrison, K., Shostak, Y., Raitano, A., Nadell, R., Liu, W., Lortie, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1313 · Cited by 724
Cancer nanotechnology: application of nanotechnology in cancer therapy
Misra, R., Acharya, S., & Sahoo, S. K. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.006 · Cited by 702
Cancer nanomedicine: from targeted delivery to combination therapy
Xu, X., Ho, W., Zhang, X., Bertrand, N., & Farokhzad, O. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.01.001 · Cited by 693
Cancer stem cell definitions and terminology: the devil is in the details
Valent, P., Bonnet, D., De Maria, R., Lapidot, T., Copland, M., Melo, J. V., Chomienne, C., Ishikawa, F., Schuringa, J. J., Stassi, G., et al. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3368 · Cited by 692
Torchilin, V. P. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00166-4 · Cited by 680
Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities
Farjadian, F., Ghasemi, A., Gohari, O., Roointan, A., Karimi, M., & Hamblin, M. R. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0120 · Cited by 664
Yu, Z., Pestell, T. G., Lisanti, M. P., & Pestell, R. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.022 · Cited by 647
Stem cell fate in cancer growth, progression and therapy resistance
Lytle, N. K., Barber, A. G., & Reya, T. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0056-x · Cited by 647
Paz-Ares, L., Vicente, D., Tafreshi, A., Robinson, A., Soto Parra, H., Mazières, J., Hermes, B., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.06.015 · Cited by 631
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 619
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers
Torchilin, V. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.09.026 · Cited by 583
Passive and Active Drug Targeting: Drug Delivery to Tumors as an Example
Torchilin, V. P. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_1 · Cited by 573
Molecular Imaging with Theranostic Nanoparticles
Jokerst, J. V., & Gambhir, S. S. (2011) · Accounts of Chemical Research · doi:10.1021/ar200106e · Cited by 548
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
nab-Paclitaxel mechanisms of action and delivery
Yardley, D. A. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.041 · Cited by 508
Drug Resistance Driven by Cancer Stem Cells and Their Niche
Prieto-Vila, M., Takahashi, R.-U., Usuba, W., Kohama, I., & Ochiya, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122574 · Cited by 508
Receptor-Mediated Endocytosis of Nanoparticles of Various Shapes
Vácha, R., Martinez-Veracoechea, F. J., & Frenkel, D. (2011) · Nano Letters · doi:10.1021/nl2030213 · Cited by 494
Silverman, J. A., & Deitcher, S. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2042-4 · Cited by 474
Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances
Xu, S., Olenyuk, B. Z., Okamoto, C. T., & Hamm-Alvarez, S. F. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.041 · Cited by 467
Magnetic Nanoparticles in Cancer Theranostics
Gobbo, O. L., Sjaastad, K., Radomski, M. W., Volkov, Y., & Prina-Mello, A. (2015) · Theranostics · doi:10.7150/thno.11544 · Cited by 462
Taxol (paclitaxel): mechanisms of action.
Horwitz, S. B. (1994) · PubMed · Cited by 434
Mahmoudi, K., Bouras, A., Bozec, D., Ivkov, R., & Hadjipanayis, C. (2018) · International Journal of Hyperthermia · doi:10.1080/02656736.2018.1430867 · Cited by 414
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Delivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 405
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Tumor microenvironment: recent advances in various cancer treatments.
Jj, W., Kf, L., & Han, F. (2018) · PubMed · doi:10.26355/eurrev_201806_15270 · Cited by 396
UV and Near-IR Triggered Release from Polymeric Nanoparticles
Fomina, N., McFearin, C., Sermsakdi, M., Edigin, O., & Almutairi, A. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102595j · Cited by 362
Biswas, S., Guix, M., Rinehart, C., Dugger, T. C., Chytil, A., Moses, H. L., Freeman, M. L., & Arteaga, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30740 · Cited by 346
The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer
Shi, Y., Riese, D. J., & Shen, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.574667 · Cited by 336
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
Dinndorf, P. A., Gootenberg, J., Cohen, M. H., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-991 · Cited by 324
Rahim, M. A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., et al. (2021) · Cancers · doi:10.3390/cancers13040670 · Cited by 323
Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0450 · Cited by 320
Discovery and Development of Therapeutic Aptamers
Bouchard, P. R., Hutabarat, R. M., & Thompson, K. M. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105547 · Cited by 320
Collier, R. J. (2001) · Toxicon · doi:10.1016/s0041-0101(01)00165-9 · Cited by 318
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Sohal, D. P. S., Duong, M., Ahmad, S. A., Gandhi, N. S., Beg, M. S., Wang-Gillam, A., Wade, J. L., Chiorean, E. G., Guthrie, K. A., Lowy, A. M., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7328 · Cited by 302
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Richards, D. A., Maruani, A., & Chudasama, V. (2017) · Chemical Science · doi:10.1039/c6sc02403c · Cited by 294
Dornan, D., Bennett, F., Chen, Y., Dennis, M., Eaton, D., Elkins, K., French, D., Go, M. A. T., Jack, A., Junutula, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205500 · Cited by 273
Trastuzumab Deruxtecan: First Approval
Keam, S. J. (2020) · Drugs · doi:10.1007/s40265-020-01281-4 · Cited by 270
Recent advances in drug delivery systems for targeting cancer stem cells
Duan, H., Liu, Y., Gao, Z., & Huang, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.016 · Cited by 256
Albumin-bound paclitaxel in solid tumors: clinical development and future directions
Kundranda, M., & Niu, J. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s88023 · Cited by 255
Vincristine Neurotoxicity: Pathophysiology and Management
Legha, S. S. (1986) · Medical Toxicology · doi:10.1007/bf03259853 · Cited by 243
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel
Immordino, M. L., Brusa, P., Arpicco, S., Stella, B., Dosio, F., & Cattel, L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00271-2 · Cited by 238
Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy522 · Cited by 237
BCMA-targeted immunotherapy for multiple myeloma
Yu, B., Jiang, T., & Liu, D. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00962-7 · Cited by 236
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review
Aubel-Sadron, G., & Londos-Gagliardi, D. (1984) · Biochimie · doi:10.1016/0300-9084(84)90018-x · Cited by 233
Germann, U. A., Furey, B. F., Markland, W., Hoover, R. R., Aronov, A. M., Roix, J. J., Hale, M., Boucher, D. M., Sorrell, D. A., Martinez-Botella, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0456 · Cited by 233
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
Saman, H., Raza, S. S., Uddin, S., & Rasul, K. (2020) · Cancers · doi:10.3390/cancers12051172 · Cited by 232
Nanostructured carriers as innovative tools for cancer diagnosis and therapy
Martinelli, C., Pucci, C., & Ciofani, G. (2019) · APL Bioengineering · doi:10.1063/1.5079943 · Cited by 228
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
Stem cells in cancer therapy: opportunities and challenges
Zhang, C.-L., Huang, T., Wu, B.-L., He, W.-X., & Liu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.20798 · Cited by 203
Nanopharmacy: Inorganic nanoscale devices as vectors and active compounds
Rivera Gil, P., Hühn, D., del Mercato, L. L., Sasse, D., & Parak, W. J. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.01.009 · Cited by 202
Thirty Years of Cancer Nanomedicine: Success, Frustration, and Hope
Salvioni, L., Rizzuto, M. A., Bertolini, J. A., Pandolfi, L., Colombo, M., & Prosperi, D. (2019) · Cancers · doi:10.3390/cancers11121855 · Cited by 201
Endotoxin Contamination: A Key Element in the Interpretation of Nanosafety Studies
Li, Y., & Boraschi, D. (2016) · Nanomedicine · doi:10.2217/nnm.15.196 · Cited by 196
Resnik, D. B., & Tinkle, S. S. (2007) · Nanomedicine · doi:10.2217/17435889.2.3.345 · Cited by 192
CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
Domanska, U. M., Timmer-Bosscha, H., Nagengast, W. B., Oude Munnink, T. H., Kruizinga, R. C., Ananias, H. J. K., Kliphuis, N. M., Huls, G., De Vries, E. G. E., de Jong, I. J., et al. (2012) · Neoplasia · doi:10.1593/neo.12324 · Cited by 191
Personalized Nanomedicine: A Revolution at the Nanoscale
Fornaguera, C., & García-Celma, M. (2017) · Journal of Personalized Medicine · doi:10.3390/jpm7040012 · Cited by 190
Ahn, H. K., Jung, M., Sym, S. J., Shin, D. B., Kang, S. M., Kyung, S. Y., Park, J.-W., Jeong, S. H., & Cho, E. K. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2498-5 · Cited by 183
Eligard: leuprolide acetate in a novel sustained-release delivery system
Sartor, O. (2003) · Urology · doi:10.1016/s0090-4295(02)02396-8 · Cited by 183
ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
Zammarchi, F., Corbett, S., Adams, L., Tyrer, P. C., Kiakos, K., Janghra, N., Marafioti, T., Britten, C. E., Havenith, C. E. G., Chivers, S., et al. (2018) · Blood · doi:10.1182/blood-2017-10-813493 · Cited by 181
Refined structure of monomelic diphtheria toxin at 2.3 Å resolution
Bennett, M. J., & Eisenberg, D. (1994) · Protein Science · doi:10.1002/pro.5560030912 · Cited by 175
Blum, J. L., Savin, M. A., Edelman, G., Pippen, J. E., Robert, N. J., Geister, B. V., Kirby, R. L., Clawson, A., & O'Shaughnessy, J. A. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.n.049 · Cited by 172
Lenos, K. J., Miedema, D. M., Lodestijn, S. C., Nijman, L. E., van den Bosch, T., Romero Ros, X., Lourenço, F. C., Lecca, M. C., van der Heijden, M., van Neerven, S. M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0179-z · Cited by 168
Li, C. H., Karantza, V., Aktan, G., & Lala, M. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1210-4 · Cited by 168
Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization
Makwana, V., Karanjia, J., Haselhorst, T., Anoopkumar‐Dukie, S., & Rudrawar, S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120117 · Cited by 159
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
Thomas, O. S., & Weber, W. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00415 · Cited by 157
Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J., & Pastan, I. H. (2002) · PubMed · Cited by 153
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Singh, A. P., Sharma, S., & Shah, D. K. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9495-8 · Cited by 150
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0391-z · Cited by 147
Roy, V., LaPlant, B. R., Gross, G. G., Bane, C. L., & Palmieri, F. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn661 · Cited by 145
Dzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 143
Yardley, D. A., Coleman, R., Conte, P., Cortés, J., Brufsky, A., Shtivelband, M. I., Young, R. R., Bengala, C., Ali, H. Y., Eakel, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy201 · Cited by 140
Cancer stem cells-emanated therapy resistance: Implications for liposomal drug delivery systems
Dianat-Moghadam, H., Heidarifard, M., Jahanban-Esfahlan, R., Panahi, Y., Hamishehkar, H., Pouremamali, F., Rahbarghazi, R., & Nouri, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.043 · Cited by 140
Pegaspargase: A Review in Acute Lymphoblastic Leukaemia
Heo, Y., Syed, Y. Y., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01120-1 · Cited by 139
Cancer stem cells: Regulation programs, immunological properties and immunotherapy
Zhang, D., Tang, D. G., & Rycaj, K. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.001 · Cited by 137
CTC-Derived Models: A Window into the Seeding Capacity of Circulating Tumor Cells (CTCs)
Tayoun, T., Faugeroux, V., Oulhen, M., Aberlenc, A., Pawlikowska, P., & Farace, F. (2019) · Cells · doi:10.3390/cells8101145 · Cited by 136
The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia
Fassas, Α., & Anagnostopoulos, Α. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500052438 · Cited by 134
Contamination of nanoparticles by endotoxin: evaluation of different test methods
Smulders, S., Kaiser, J., Zuin, S., LANDUYT, K. L. V., Golanski, L., Vanoirbeek, J. A., Wick, P., & Hoet, P. (2012) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-9-41 · Cited by 132
Green, D. S., Bodman‐Smith, M. D., Dalgleish, A. G., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07664.x · Cited by 128
Review of mifamurtide in the treatment of patients with osteosarcoma
Kager, L., Pötschger, U., & Bielack (2010) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s5688 · Cited by 126
Markers of pancreatic cancer stem cells and their clinical and therapeutic implications
Gzil, A., Zarębska, I., Bursiewicz, W., Antosik, P., Grzanka, D., & Szylberg, Ł. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05058-1 · Cited by 124
Tolcher, A. W., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Martinez, D., Wood, D. L., Fielman, B. A., Sharma, M., Janisch, L. A., Brown, B. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.11006 · Cited by 121
How to escape the cancer attractor: Rationale and limitations of multi-target drugs
Huang, S., & Kauffman, S. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.003 · Cited by 118
From Conventional to Stealth Liposomes: a New Frontier in Cancer Chemotherapy
Cattel, L., Ceruti, M., & Dosio, F. (2004) · Journal of Chemotherapy · doi:10.1179/joc.2004.16.supplement-1.94 · Cited by 117
Perez, A., Domenech, G. H., Frankel, C., & Vogel, C. L. (2002) · Cancer Investigation · doi:10.1081/cnv-120014883 · Cited by 114
Chuang, L. I. U., Luo, L., Zeng, L., Xing, J., Xia, Y., Sun, S., Zhang, L., Yu, Z., Yao, J., Yu, Z., et al. (2018) · Small · doi:10.1002/smll.201801851 · Cited by 114
Tumor microenvironment and nanotherapeutics.
Upreti, M., Jyoti, A., & Sethi, P. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.08.11 · Cited by 107
Bernstein, I. D. (2000) · Leukemia · doi:10.1038/sj.leu.2401663 · Cited by 105
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Frampton, J. E. (2020) · Drugs · doi:10.1007/s40265-020-01336-6 · Cited by 104
Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells: A Review of Recent Advances
Ertaş, Y. N., Dorcheh, K. A., Akbari, A., & Jabbari, E. (2021) · Nanomaterials · doi:10.3390/nano11071755 · Cited by 103
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
Salazar, L. G., Lu, H., Reichow, J. L., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6007 · Cited by 101
Hosein, P. J., Lopes, G. D. L., Jr., Pastorini, V. H., Gomez, C., MacIntyre, J., Zayas, G., dos Reis, I. M., Montero, A. J., Merchan, J. R., & Lima, C. M. R. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182436e8c · Cited by 99
DiJoseph, J. F., Goad, M. E. P., Dougher, M. M., Boghaert, E. R., Kunz, A., Hamann, P. R., & Damle, N. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1134 · Cited by 99
Havel, H. A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9970-6 · Cited by 99
Kottschade, L. A., Suman, V. J., AMATRUDA, T. T., McWilliams, R. R., Mattar, B. I., Nikcevich, D. A., Behrens, R. J., Fitch, T. R., Jaslowski, A. J., & Markovic, S. N. (2010) · Cancer · doi:10.1002/cncr.25659 · Cited by 98
Conlin, A. K., Seidman, A. D., Bach, A. M., Lake, D. E., Dickler, M. N., D’Andrea, G. M., Traina, T. A., Danso, M. A., Brufsky, A., Saleh, M. N., et al. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.036 · Cited by 91
Nanomaterials in cancer: Reviewing the combination of hyperthermia and triggered chemotherapy
Ribeiro, T. P., Moreira, J. A., Monteiro, F. J., & Laranjeira, M. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.045 · Cited by 90
Nahleh, Z. A., Barlow, W. E., Hayes, D. F., Schott, A. F., Gralow, J. R., Sikov, W. M., Perez, E. A., Chennuru, S., Mirshahidi, H., Corso, S. W., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3889-6 · Cited by 87
Opportunities and challenges in commercial pharmaceutical liposome applications
Jensen, G. M., & Hodgson, D. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.016 · Cited by 87
Kottschade, L. A., Suman, V. J., Pérez, D. G., McWilliams, R. R., Kaur, J. S., AMATRUDA, T. T., Geoffroy, F. J., Gross, H. M., Cohen, P. A., Jaslowski, A. J., et al. (2012) · Cancer · doi:10.1002/cncr.27760 · Cited by 84
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic
Fraguas‐Sánchez, A. I., Lozza, I., & Torres‐Suárez, A. I. (2022) · Cancers · doi:10.3390/cancers14051198 · Cited by 84
Selective depletion of metastatic stem cells as therapy for human colorectal cancer
Céspedes, M. V., Unzueta, U., Aviñó, A. M., Gallardo, A., Álamo, P., Sala, R., Sánchez‐Chardi, A., Casanova, I., Mangues, M. A., Pousa, A. L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708772 · Cited by 83
Self-citationMiltefosine as a topical treatment for cutaneous metastases in breast carcinoma
Clive, S., Gardiner, J., & Léonard, R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051114 · Cited by 81
Teneriello, M. G., Tseng, P. C., Crozier, M., Encarnacion, C. A., Hancock, K. C., Messing, M. J., Boehm, K. A., Williams, A., & Asmar, L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9548 · Cited by 80
Yang, P., Hu, Y., & Zhou, Q. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191113113110 · Cited by 80
Aspartate β-hydroxylase as a target for cancer therapy
Kanwal, M., Šmahel, M., Olsen, M. J., Šmahelová, J., & Tachezy, R. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01669-w · Cited by 79
Bukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 79
The yin and yang of imaging tumor associated macrophages with PET and MRI
Mukherjee, S., Sonanini, D., Maurer, A., & Daldrup-Link, H. E. (2019) · Theranostics · doi:10.7150/thno.37306 · Cited by 77
Sanoff, H. K., Moon, D. H., Moore, D. T., Boles, J., Bui, C., Blackstock, W., O'Neil, B. H., Subramaniam, S., McRee, A. J., Carlson, C., et al. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.021 · Cited by 72
Polymers, responsiveness and cancer therapy
Pethe, A. M., & Yadav, K. S. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1559176 · Cited by 68
Alberts, D. S., Blessing, J. A., Landrum, L. M., Warshal, D. P., Martin, L. P., Rose, S. L., Bonebrake, A. J., & Ramondetta, L. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.09.008 · Cited by 67
Connolly, R. M., Leal, J. P., Goetz, M. P., Zhang, Z., Zhou, X. C., Jacobs, L. K., Mhlanga, J. C., Joo Hyun, O., Carpenter, J. T., Storniolo, A. M., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.144741 · Cited by 67
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India
Ranade, A. A., Joshi, D. A., Phadke, G. K., Patil, P. P., Kasbekar, R. B., Apte, T. G., Dasare, R. R., Mengde, S. D., Parikh, P. M., Bhattacharyya, G. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt322 · Cited by 64
Targeting the Colorectal Cancer Stem Cell
Medema, J. P. (2017) · New England Journal of Medicine · doi:10.1056/nejmcibr1706541 · Cited by 63
Hamilton, E. P., Kimmick, G. G., Hopkins, J. O., Marcom, P. K., Rocha, G., Welch, R. A., Broadwater, G., & Blackwell, K. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.08.003 · Cited by 62
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
Cheng, Y., Zhang, L., Hu, J., Wang, D., Hu, C., Zhou, J., Wu, L., Cao, L., Liu, J., Zhang, H., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100225 · Cited by 60
Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator.
Chen, Y., Liu, R., Li, C., Song, Y., Liu, G., Huang, Q., Yu, L., Zhu, D., Lu, C. C., Lü, A., et al. (2021) · American Journal of Cancer Research · Cited by 58
Nanoliposomes as drug delivery systems: safety concerns
Tereshkina, Y. A., Torkhovskaya, T. I., Tikhonova, E. G., Kostryukova, L. V., Sanzhakov, M. A., Korotkevich, E. I., Khudoklinova, Y. Y., Orlova, N. A., & Kolesanova, E. F. (2021) · Journal of drug targeting · doi:10.1080/1061186x.2021.1992630 · Cited by 47
Ontak-like human IL-2 fusion toxin
Wang, Z., Zheng, Q., Zhang, H., Bronson, R. T., Madsen, J. C., Sachs, D. H., Huang, C. A., & Wang, Z. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.05.008 · Cited by 43
Design of smart nanomedicines for effective cancer treatment
Aghda, N. H., Dabbaghianamiri, M., Tunnell, J. W., & Betancourt, T. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121791 · Cited by 40
S̄pitler, L. E., Boasberg, P. D., Day, S. O., Hamid, O., Cruickshank, S., Mesko, S. M., & Weber, R. W. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318287bbae · Cited by 38
Symonds, L. K., Linden, H. M., Gadi, V. K., Korde, L. A., Rodler, E. T., Gralow, J. R., Redman, M. W., Baker, K. K., Wu, Q. V., Jenkins, I., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.008 · Cited by 37
Domańska, U., Boer, J. C., Timmer‐Bosscha, H., van Vugt, M. A. T. M., Hoving, H. D., Kliphuis, N. M., Rosati, S., van der Poel, H. G., de Jong, I. J., de Vries, E. G. E., et al. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9673-2 · Cited by 34
Nanomedicine in cancer stem cell therapy: from fringe to forefront
Tabassum, N., Verma, V., Kumar, M., Kumar, S. K. A., & Singh, B. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2928-5 · Cited by 34
Kaklamani, V., Siziopikou, K. P., Scholtens, D. M., Lacouture, M. E., Gordon, J., Uthe, R., Meservey, C., Hansen, N. M., Khan, S. A., Jeruss, J. S., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1411-8 · Cited by 33
Current Clinical Indications for Plerixafor
Früehauf, S. (2013) · Transfusion Medicine and Hemotherapy · doi:10.1159/000354229 · Cited by 33
Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective
Tang, Y., Chen, Y., Zhang, Z., Tang, B., Zhou, Z., & Chen, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122116 · Cited by 33
Marcucci, F., Caserta, C. A., Romeo, E. L., & Rumio, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00167 · Cited by 32
A Concise Review: The Role of Stem Cells in Cancer Progression and Therapy
Hayat, H., Hayat, H., Dwan, B. F., Gudi, M., Bishop, J. O., & Wang, P. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s260391 · Cited by 29
Cohen, A. L., Ray, A., Brocklin, M. W. V., Burnett, D. M., Bowen, R. C., Dyess, D. L., Butler, T. W., Dumlao, T. L., & Khong, H. T. (2016) · Oncotarget · doi:10.18632/oncotarget.14183 · Cited by 28
A nano-based thermotherapy for cancer stem cell-targeted therapy
Suo, X., Zhang, J., Zhang, Y., Liang, X., Zhang, J., & Liu, D. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00311e · Cited by 28
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
Quintanilha, J. C. F., Wang, J., Sibley, A. B., Jiang, C., Etheridge, A. S., Shen, F., Jiang, G., Mulkey, F. A., Patel, J. N., Hertz, D. L., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01557-w · Cited by 26
nab -paclitaxel for the management of patients with advanced non-small-cell lung cancer
Hirsh, V. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.881719 · Cited by 22
FDA approves liposomal vincristine (Marqibo) for rare leukemia.
Ingram, I. (2012) · PubMed · Cited by 21
Nakamura, K., Kiminami, H., Yamashita, A., Abe, Y., Yoshino, K., & Suzuki, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.020 · Cited by 18
Recent Advances in Fabrication of Well-Organized Protein-Based Nanostructures
Zhang, J.-T., Ma, J., Kankala, R. K., Yu, Q., Wang, S., & Chen, A. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00156 · Cited by 17
Feliú, J., Fernández, M. J., Macarulla, T. M., Massutí, B., Albero, A., González, J. F. G., Aldana, G. Q., Delgado-Mingorance, J. I., Montés, A. F., Piernavieja, C. G., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04214-w · Cited by 16
Jazrawi, A., Pantiora, E. V., Abdsaleh, S., et al. (2021) · Cancers · doi:10.3390/cancers13174285 · Cited by 16
Mashima, T. (2017) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.16-00229-1 · Cited by 15
Adkins, D. R., Ley, J. C., Oppelt, P., Gay, H. A., Daly, M. D., Paniello, R. C., Jackson, R. S., Pipkorn, P. J., Rich, J. T., Zevallos, J. P., et al. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.05.007 · Cited by 15
Tzogani, K., Straube, M., Hoppe, U., Kiely, P., O’Dea, G., Enzmann, H. G., Salmon, P., Salmonson, T., & Pignatti, F. (2013) · Journal of Dermatological Treatment · doi:10.3109/09546634.2013.789474 · Cited by 12
Current treatment strategies and emerging therapies for cutaneous lymphoma
Yonekura, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.16289 · Cited by 10
(1995) · PubMed · Cited by 8
Cited by
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
Yun, W. S., Kim, J., Lim, D.-K., Kim, D.-H., Jeon, S. I., & Kim, K. (2023) · Nanomaterials · doi:10.3390/nano13152225 · Cited by 76
Metadata
- Authors
- Rodríguez, F., Caruana, P., De la Fuente, N., Español, P., Gámez, M., Balart, J., Llurba, E., Rovira, R., Ruiz, R., Martín-Lorente, C., Corchero, J. L., & Céspedes, M. V.
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2022-06-04
- Volume
- 12
- Issue
- 6
- Pages
- 784
- ISSN
- 2218-273X (ISSN-L)
- OpenAlex
- W4281769542
- Cited by
- 274
- References
- 188
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.